Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer

The usual approach to care for hormone receptor positive, HER2 positive breast cancer is chemotherapy and HER2 targeted therapy followed by endocrine therapy and surgery. The purpose of this Research Study is to see if taking endocrine therapy with the chemotherapy and HER2 directed therapy increases patients response to therapy at the time of surgery

Trial Details

NCT ID
NCT07506876
Phase
PHASE2
Sponsor
Legacy Health System
Status
RECRUITING
Cancer Type
ER/PR Positive (Hormone Receptor Positive) Breast Cancer
Interventions
  • Concurrent endocrine therapy with the chemotherapy and HER2 directed therapy
Locations (sample)
  • Gresham, Oregon, United States|45.49818,-122.43148
  • Portland, Oregon, United States|45.52345,-122.67621
  • Tualatin, Oregon, United States|45.38401,-122.76399
  • Vancouver, Washington, United States|45.63873,-122.66149

Key Eligibility Criteria

  • Adults over 18 years of age with newly diagnosed, previously untreated, HR+, HER2+ breast cancer (positive per local guidelines)
  • Endocrine therapy for the current breast cancer may be started within 28 days prior to trial enrollment and must be initiated prior to C2 of chemot…
  • Choice of endocrine therapy will be determined by the treating and/or enrolling physician
  • Anatomic Stage IIA - IIIC breast cancer planning a minimum of 4 cycles of TCHP

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find ER/PR Positive (Hormone Receptor Positive) Breast Cancer Trials on Trialify →